anti-214(MicroMedMark)

N/A

Report date: 2025/08/07 09:46:12

Base Information

Drug Nameanti-214(MicroMedMark)
Drug Alias Nameanti‑miRNA‑214(MicroMedMark)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionProto-oncogene proteins c-akt inhibitorsPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN inhibitors
TargetsProto-oncogene proteins c-aktPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Mingma Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Mingma Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A